ALLURION TECHNOLOGIES, INC. (ALUR): restructuring charge — Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy

ALLURION TECHNOLOGIES, INC.

2025-Q2 EPS reported -$1.79 revenue$8,959,000

Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.
Restructuring: workforce reduction of ~70 employees (~65% of total); estimated severance charges of ~$1.5M; completion expected by end of Q3 2025.
Signed term sheet with strategic partner for ex-US distribution and potential joint development of a GLP-1 drug-eluting intragastric balloon.
Submitted protocol to IRBs for prospective study on low-dose GLP-1 + Allurion Program for weight loss and muscle preservation; enrollment expected in 2025.
PMA application for Allurion Balloon accepted by FDA for evaluation.

item 2.02 item 2.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

ALLURION TECHNOLOGIES, INC. announced a restructuring with charges of approximately $1.5 million (approximately 70 employees, or approximately 65% of its workforce).

Type: restructuring
Charge: approximately $1.5 million
Headcount: approximately 70 employees, or approximately 65% of its workforce

Exact text from the filing

employees between August 4, 2025 and August 6, 2025. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $1.5 million. The Company’s estimated restructuring charges is based on a number of assumptions. Actual results may differ materially and the Company may also incur other charges or cash

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

ALLURION TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-104347

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.